A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

ClinicalTrials.gov ID: NCT02576275

Public ClinicalTrials.gov record NCT02576275. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).

Study identification

NCT ID: NCT02576275
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 3
Lead sponsor: SecuraBio; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2015 (Type not available)
Primary completion: Nov 2016 (Actual)
Completion: Nov 2016 (Actual)
Last update posted: Mar 17, 2021

2015 – 2016

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Not listed	Plainville	Connecticut	06062	—
Not listed	Plantation	Florida	33322	—
Not listed	Thomasville	Georgia	31792	—
Not listed	East Setauket	New York	11733-3456	—
Not listed	Cookeville	Tennessee	38501	—
Not listed	Knoxville	Tennessee	37909	—
Not listed	Spokane	Washington	99208	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02576275, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 17, 2021 · Synced Nov 1, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02576275 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →